$14.67
5.78% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$15.57
-3.56 18.61% 1M
-13.68 46.77% 6M
-10.13 39.42% YTD
-26.58 63.06% 1Y
+3.46 28.57% 3Y
+11.98 333.70% 5Y
+4.38 39.14% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.78 4.77%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $1.36b
Enterprise Value $705.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 100.83
P/S ratio (TTM) P/S ratio 194.71
P/B ratio (TTM) P/B ratio 1.27
Revenue growth (TTM) Revenue growth -70.07%
Revenue (TTM) Revenue $7.00m
EBIT (operating result TTM) EBIT $-326.98m
Free Cash Flow (TTM) Free Cash Flow $-251.44m
Cash position $676.32m
EPS (TTM) EPS $-3.30
P/E forward negative
P/S forward 84.88
EV/Sales forward 43.95
Short interest 12.57%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a IDEAYA Biosciences Inc forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
92%
Hold
8%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
7 7
70% 70%
100%
- Direct Costs 3.83 3.83
4% 4%
55%
3.17 3.17
84% 84%
45%
- Selling and Administrative Expenses 32 32
55% 55%
452%
- Research and Development Expense 295 295
128% 128%
4,210%
-323 -323
148% 148%
-4,616%
- Depreciation and Amortization 3.83 3.83
4% 4%
55%
EBIT (Operating Income) EBIT -327 -327
143% 143%
-4,671%
Net Profit -274 -274
143% 143%
-3,921%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Negative
Seeking Alpha
2 days ago
Ideaya Biosciences, Inc.'s stock has plummeted ~50% due to macroeconomic factors, Trump administration policies, and specific company challenges, impacting the entire biopharma sector. Trump's FDA policies and tariffs have disrupted IDYA's regulatory approvals and increased manufacturing costs, particularly affecting their Chinese supply chains. Despite market sentiment and analyst downgrades, ...
Neutral
PRNewsWire
3 days ago
SOUTH SAN FRANCISCO, Calif. , April 1, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events.
Neutral
PRNewsWire
4 days ago
Designation enables expedited development and priority regulatory review BTD application was supported by updated clinical data from Ph2 neoadjuvant UM trial that we are targeting to present at medical conferences in mid-2025 and H2 2025 Targeting to initiate a Ph3 registrational study in neoadjuvant UM in H1 2025 Neoadjuvant UM has a projected annual incidence of ~12k patients, and is a high u...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 131
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today